Nanoparticles for the treatment of visceral leishmaniasis: review
Source abstract
Abstract
Visceral leishmaniasis is an infectious disease caused by the protozoan Leishmania. Due to the lack of vaccines and the limitations of current treatment (toxicity, serious adverse effects, and high cost), new therapeutic options must be developed. This work aims to perform a systematic review focusing on studies that use nanoparticles to treat visceral leishmaniasis, with in vivo tests to evaluate the antileishmanial effect. The search was carried out between January 2011 and August 2021 in the PubMed and Web of Science databases, using the keywords “visceral leishmaniasis and nanoparticles and in vivo.” The articles were selected through inclusion and exclusion criteria. After the analysis, 26 articles were selected containing polymeric, lipidic, metallic, and inorganic nanoparticles. As for the nanometric size, the polymeric and lipid nanoparticles showed size ranges from 138 to 377.9 nm and 103.7 to 266.3 nm, respectively. The inorganic nanoparticles had a size of around 140 nm. Also, the metallic nanoparticles showed sizes of 58.6, 134.3, and 142.7 nm. In addition, amphotericin B was the most used drug. In some studies, drug co-encapsulation was performed, which is a future trend, useful to increase the therapeutic efficacy of the treatment. The studies showed that the use of nanoparticles for drug delivery was able to reduce the parasite burden and toxicity. Nanoparticles can increase the efficacy and safety of the treatment, suggesting a promising option for visceral leishmaniasis treatment. Graphical Abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Research on Leishmaniasis Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Tiuman TS, Santos AO, Ueda-Nakamura T et al (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15:e525–e532. https://doi.org/10.1016/j.ijid.2011.03.02110.1016/j.ijid.2011.03.021 ↗
2. McGwire BS, Satoskar AR (2014) Leishmaniasis: clinical syndromes and treatment. QJM 107:7–14. https://doi.org/10.1093/qjmed/hct11610.1093/qjmed/hct116 ↗
3. Chávez-Fumagalli MA, Ribeiro TG, Castilho RO et al (2015) New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment. Rev Soc Bras Med Trop 48:235–24210.1590/0037-8682-0138-2015 ↗
4. Steverding D (2017) The history of leishmaniasis. Parasit Vectors 10:82. https://doi.org/10.1186/s13071-017-2028-510.1186/s13071-017-2028-5 ↗
5. Volpedo G, Costa L, Ryan N, et al (2019) Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases. J Venom Anim Toxins Incl Trop Dis 25:e144118. https://doi.org/10.1590/1678-9199-jvatitd-1441-1810.1590/1678-9199-jvatitd-1441-18 ↗
6. Khatik R, Dwivedi P, Khare P et al (2014) Development of targeted 1,2-diacyl-sn-glycero-3-phospho- L-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis. Expert Opin Drug Deliv 11:633–646. https://doi.org/10.1517/17425247.2014.88967810.1517/17425247.2014.889678 ↗
7. Corpas-López V, Díaz-Gavilán M, Franco-Montalbán F et al (2019) A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis. Pharmacol Res 139:375–383. https://doi.org/10.1016/j.phrs.2018.11.03910.1016/j.phrs.2018.11.039 ↗
8. Bi K, Chen Y, Zhao S et al (2018) Current visceral leishmaniasis research: a research review to inspire future study. Biomed Res Int 2018:1–13. https://doi.org/10.1155/2018/987209510.1155/2018/9872095 ↗
9. Matos APS, Viçosa AL, Ré MI et al (2020) A review of current treatments strategies based on paromomycin for leishmaniasis. J Drug Deliv Sci Technol 57:101664. https://doi.org/10.1016/j.jddst.2020.10166410.1016/j.jddst.2020.101664 ↗
10. Kumar R, Sahoo GC, Pandey K et al (2016) Development of PLGA–PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis. Mater Sci Eng C 59:748–753. https://doi.org/10.1016/j.msec.2015.10.08310.1016/j.msec.2015.10.083 ↗
11. Singh PK, Jaiswal AK, Pawar VK et al (2018) Fabrication of 3-O-sn-phosphatidyl-L-serine anchored PLGA nanoparticle bearing amphotericin B for macrophage targeting. Pharm Res 35:60. https://doi.org/10.1007/s11095-017-2293-110.1007/s11095-017-2293-1 ↗
12. Costa Lima SA, Silvestre R, Barros D et al (2014) Crucial CD8+ T-lymphocyte cytotoxic role in amphotericin B nanospheres efficacy against experimental visceral leishmaniasis. Nanomedicine Nanotechnology, Biol Med 10:e1021–e1030. https://doi.org/10.1016/j.nano.2013.12.01310.1016/j.nano.2013.12.013 ↗
13. Singh OP, Gedda MR, Mudavath SL et al (2019) Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. Nanomedicine 14:1911–1927. https://doi.org/10.2217/nnm-2018-044810.2217/nnm-2018-0448 ↗
14. Bayda S, Adeel M, Tuccinardi T et al (2019) The history of nanoscience and nanotechnology: from chemical–physical applications to nanomedicine. Molecules 25:112. https://doi.org/10.3390/molecules2501011210.3390/molecules25010112 ↗
15. Kokila NR, Mahesh B, Roopa KP et al (2022) Thunbergia mysorensis mediated nano silver oxide for enhanced antibacterial, antioxidant, anticancer potential and in vitro hemolysis evaluation. J Mol Struct 1255:132455. https://doi.org/10.1016/j.molstruc.2022.13245510.1016/j.molstruc.2022.132455 ↗
16. Chamaraja NA, Mahesh B, Praveen Kumar CB (2021) Colorimetric detection of chromium (VI) using peroxidase mimetic IONPS with 4- Aminoantipyrene and 3-Aminophenol as a chromogen. Environ Nanotechnology, Monit Manag 16:100471. https://doi.org/10.1016/j.enmm.2021.10047110.1016/j.enmm.2021.100471 ↗
17. Chamaraja NA, Mahesh B, Rekha ND (2022) Green synthesis of Zn/Cu oxide nanoparticles by Vernicia fordii seed extract: their photocatalytic activity toward industrial dye degradation and their biological activity. Inorg Nano-Metal Chem 1–13. https://doi.org/10.1080/24701556.2022.206912310.1080/24701556.2022.2069123 ↗
18. Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385:113–142. https://doi.org/10.1016/j.ijpharm.2009.10.01810.1016/j.ijpharm.2009.10.018 ↗
19. Akbari M, Oryan A, Hatam G (2017) Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop 172:86–90. https://doi.org/10.1016/j.actatropica.2017.04.02910.1016/j.actatropica.2017.04.029 ↗
20. Cruz R, Calasans-Maia J, Sartoretto S et al (2018) Does the incorporation of zinc into calcium phosphate improve bone repair? A systematic review. Ceram Int 44:1240–1249. https://doi.org/10.1016/j.ceramint.2017.10.15710.1016/j.ceramint.2017.10.157 ↗
21. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372(71):1-13. https://doi.org/10.1136/bmj.n7110.1136/bmj.n71 ↗
22. Valle IV, Machado ME, da Araújo C, CB, et al (2019) Oral pentamidine-loaded poly(d, l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment. Nanotechnology 30:455102. https://doi.org/10.1088/1361-6528/ab373e10.1088/1361-6528/ab373e ↗
23. Chaubey P, Mishra B, Mudavath SL et al (2018) Mannose-conjugated curcumin-chitosan nanoparticles: efficacy and toxicity assessments against Leishmania donovani. Int J Biol Macromol 111:109–120. https://doi.org/10.1016/j.ijbiomac.2017.12.14310.1016/j.ijbiomac.2017.12.143 ↗
24. Tripathi P, Jaiswal AK, Dube A, Mishra PR (2017) Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani. Int J Biol Macromol 105:625–637. https://doi.org/10.1016/j.ijbiomac.2017.07.07610.1016/j.ijbiomac.2017.07.076 ↗
25. Das S, Ghosh S, De AK, Bera T (2017) Oral delivery of ursolic acid-loaded nanostructured lipid carrier coated with chitosan oligosaccharides: development, characterization, in vitro and in vivo assessment for the therapy of leishmaniasis. Int J Biol Macromol 102:996–1008. https://doi.org/10.1016/j.ijbiomac.2017.04.09810.1016/j.ijbiomac.2017.04.098 ↗
26. Asthana S, Jaiswal AK, Gupta PK et al (2013) Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother 57:1714–1722. https://doi.org/10.1128/AAC.01984-1210.1128/AAC.01984-12 ↗
27. Costa Lima SA, Resende M, Silvestre R et al (2012) Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies. Nanomedicine 7:1839–1849. https://doi.org/10.2217/nnm.12.7410.2217/nnm.12.74 ↗
28. Asthana S, Gupta PK, Jaiswal AK et al (2015) Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies. Nanomedicine 10:1093–1109. https://doi.org/10.2217/nnm.14.18210.2217/nnm.14.182 ↗
29. Tiwari B, Pahuja R, Kumar P et al (2017) Nanotized curcumin and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. Antimicrob Agents Chemother 61(3):e01169-16. https://doi.org/10.1128/AAC.01169-1610.1128/AAC.01169-16 ↗
30. Gupta PK, Jaiswal AK, Asthana S et al (2015) Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis. Pharm Res 32:1727–1740. https://doi.org/10.1007/s11095-014-1571-410.1007/s11095-014-1571-4 ↗
31. Asthana S, Gupta PK, Jaiswal AK et al (2015a) Overexpressed macrophage mannose receptor targeted nanocapsules- mediated cargo delivery approach for eradication of resident parasite: in vitro and in vivo studies. Pharm Res 32: 2663–2677. https://doi.org/10.1007/s11095-015-1651-010.1007/s11095-015-1651-0 ↗
32. Ray L, Karthik R, Srivastava V et al (2021) Efficient antileishmanial activity of amphotericin B and piperine entrapped in enteric coated guar gum nanoparticles. Drug Deliv Transl Res 11:118–130. https://doi.org/10.1007/s13346-020-00712-910.1007/s13346-020-00712-9 ↗
33. Ghosh S, Kar N, Bera T (2016) Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis. Int J Biol Macromol 93:961–970. https://doi.org/10.1016/j.ijbiomac.2016.09.01410.1016/j.ijbiomac.2016.09.014 ↗
34. Kansal S, Tandon R, Dwivedi P et al (2012) Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. J Antimicrob Chemother 67:2650–2660. https://doi.org/10.1093/jac/dks28610.1093/jac/dks286 ↗
35. Jesus JA, Sousa IMO, da Silva TNF et al (2021) Preclinical assessment of ursolic acid loaded into nanostructured lipid carriers in experimental visceral leishmaniasis. Pharmaceutics 13:908. https://doi.org/10.3390/pharmaceutics1306090810.3390/pharmaceutics13060908 ↗
36. Lopes RM, Gaspar MM, Pereira J et al (2014) Liposomes versus lipid nanoparticles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis. J Biomed Nanotechnol 10:3647–3657. https://doi.org/10.1166/jbn.2014.187410.1166/jbn.2014.1874 ↗
37. Thapa R, Mondal S, Riikonen J et al (2021) Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. PLoS Negl Trop Dis 15:e0009533. https://doi.org/10.1371/journal.pntd.000953310.1371/journal.pntd.0009533 ↗
38. Asthana S, Jaiswal AK, Gupta PK et al (2015) Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid–polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B. Eur J Pharm Biopharm 89:62–73. https://doi.org/10.1016/j.ejpb.2014.11.01910.1016/j.ejpb.2014.11.019 ↗
39. Ghosh S, Das S, De AK et al (2017) Amphotericin B-loaded mannose modified poly(D, L-lactide-co-glycolide) polymeric nanoparticles for the treatment of visceral leishmaniasis: in vitro and in vivo approaches. RSC Adv 7:29575–29590. https://doi.org/10.1039/C7RA04951J10.1039/C7RA04951J ↗
40. Silva DF, Reis LES, Machado MGC et al (2021) Repositioning of tamoxifen in surface-modified nanocapsules as a promising oral treatment for visceral leishmaniasis. Pharmaceutics 13:1061. https://doi.org/10.3390/pharmaceutics1307106110.3390/pharmaceutics13071061 ↗
41. Parvez S, Yadagiri G, Gedda MR et al (2020) Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep 10:12243. https://doi.org/10.1038/s41598-020-69276-510.1038/s41598-020-69276-5 ↗
42. Chaurasia M, Pawar VK, Jaiswal AK et al (2015) Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response. Int J Biol Macromol 79:27–36. https://doi.org/10.1016/j.ijbiomac.2015.04.04310.1016/j.ijbiomac.2015.04.043 ↗
43. Kansal S, Tandon R, Verma A et al (2014) Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against L eishmania in hamsters by inducing Th1-type immune responses. Br J Pharmacol 171:4038–4050. https://doi.org/10.1111/bph.1275410.1111/bph.12754 ↗
44. Xu R (2008) Progress in nanoparticles characterization: sizing and zeta potential measurement. Particuology 6:112–115. https://doi.org/10.1016/j.partic.2007.12.00210.1016/j.partic.2007.12.002 ↗
45. Habanjar O, Diab-Assaf M, Caldefie-Chezet F, Delort L (2021) 3D cell culture systems: tumor application, advantages, and disadvantages. Int J Mol Sci 22:12200. https://doi.org/10.3390/ijms22221220010.3390/ijms222212200 ↗
46. Matai I, Kaur G, Seyedsalehi A et al (2020) Progress in 3D bioprinting technology for tissue/organ regenerative engineering. Biomaterials 226:119536. https://doi.org/10.1016/j.biomaterials.2019.11953610.1016/j.biomaterials.2019.119536 ↗